About

Company description

Catalyst + Talent

Our name combines these ideas. From drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. With over 75 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing results.

We serve thousands of innovators, large and small, in over 100 markets, including 36 of the top 50 biotech companies and 49 of the top 50 pharmaceutical companies. Our team of over 1,000 talented scientists supports 40% of recent new drug approvals, and our nearly 30 global sites make or package over 100 billion units annually. Our significant intellectual property in oral, injectable, and respiratory dosage forms and advanced drug packaging includes over 1,200 patents and patent applications.

Quick facts

Sales markets Asia, North America
Affiliated categories: API Contract Manufacturing |Bio Analytical Services |Biotechnology and related specialities More

Upcoming events

30 apr 2019

CPhI North America 2019

30 April - 2 May 2019 Chicago, USA Visit us at stand 1206 Book a meeting See our Exhibitor Profile   See full Exhibitor List

Recently at

9 oct 2018

CPhI Worldwide 2018

9 - 11 October 2018 Madrid, Spain We were at stand 3D10 See our Exhibitor Profile   See full Exhibitor List
24 apr 2018

CPhI North America 2018

24-26 April, 2018 Philadelphia, USA We were at stand 1401 See our Exhibitor Profile   See full Exhibitor List
24 oct 2017

CPhI Worldwide 2017

24 - 26 October 2017 Messe Frankfurt, Germany We were at stand 41G10 See our Exhibitor Profile   See full Exhibitor List

News about Catalent

Catalent invests over $27 million to commercialize Zydis Ultra

7 Mar 2019

Catalent invests over $27 million to commercialize Zydis Ultra

Zydis Ultra allows a patented and innovative drug coating to be introduced during a product’s formulation, enabling the dosage of active ingredient to be up to four times higher than a conventional Zydis ODT.

Read more

19 Feb 2019

Catalent receives P&G External Business Partner of the Year Award

The award recognizes the performance of Catalent’s two state-of-the-art softgel manufacturing facilities in Ontario, Canada.

Read more

7 Jan 2019

Catalent to double its commercial biomanufacturing capacity

The $200-million expansion will support customers’ development programs and commercial launches.

Read more

3 Dec 2018

Catalent to expand biologics packaging capabilities

Company's $14 million investment follows twentieth commercial drug approval at Bloomington, Indiana site.

Read more